- Home
- ECBK vs ABOS Comparison
ECBK vs ABOS Comparison
Compare ECBK & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECBK | ABOS |
|---|---|---|
| Founded | 1919 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.3M | 155.7M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ECBK | ABOS |
|---|---|---|
| Price | $16.90 | $2.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 7.2K | ★ 473.4K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.55 | $0.86 |
| 52 Week High | $20.05 | $3.60 |
Technical Indicators
Market Signals| Indicator | ECBK | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 39.88 | 38.88 |
| Support Level | $15.86 | $1.21 |
| Resistance Level | $16.53 | $3.05 |
| Average True Range (ATR) | 0.45 | 0.26 |
| MACD | -0.06 | -0.11 |
| Stochastic Oscillator | 13.53 | 7.41 |
Price Performance
Historical ComparisonAbout ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.